Dr Abusnina is a data scientist at Boehringer Ingelheim Digital lab (BI X) where he and his colleagues are building the next generation of scientist-trusted intelligent biopharmaceutical processes. Before he joined BI X he worked for about two years as a senior associate in Artificial Intelligence and Analytics group at Cognizant technology solutions. Dr. Abusnina spent fours years in the chemical industry working for Evonik Industries where he also did his doctorate internship in data driven modelling. He holds engineering doctorate degree from the university of York – UK in Large Scale Complex IT Systems, and MSc in smart systems and Technology from University of Bournemouth - UK.
Dr. Baghbaderani is the global head of Process Development, Emerging Technologies at Lonza. He has over 15 years of experience in stem cells engineering, bioprocessing, and cell and gene therapy (C>) field. Dr. Baghbaderani holds a PhD degree in Biomedical Engineering from the University of Calgary (Calgary, Canada), where he developed bioreactor protocols for large-scale expansion of human neural stem cells for clinical applications. He completed nearly three years of postdoctoral program including a two-year postdoctoral fellowship at the National Institutes of Health (NIH) / National Institute of Neurological Disorders and Stroke (NINDS). His postdoctoral research at the NIH focused on generation of human induced pluripotent stem cells, bioprocessing of both human embryonic stem cells and human iPSCs and controlled differentiation into neuronal lineage. Since joining Lonza in 2011, he has been working on developing new technologies and manufacturing processes around human pluripotent stem cells. Dr. Baghbaderani then led the cell therapy development department (including process development and bioassay services), focusing on the development of cGMP compliant processes and cell characterization assays for different cell therapy applications. As the global head of process development, Dr. Baghbaderani is currently leading the development activities for viral vector and C> applications across Lonza network.
Dr. Bhardwaj completed his education and training at IIT Bombay, FH Pforzheim, MIT Sloan, and EBS Oestrich-Winkel. He worked for BCG and EY before founding Innoplexus in 2011 and since then has been CEO. He accompanied minister president Oettinger, the minister of economic affairs from Baden-Württemberg Pfister and health minister Bahr for delegation trips. Dr. Bhardwaj is the author of 12 patent applications. He has authored several publications in the Harvard Business Review, MIT Sloan Review, the Journal of Tumour Medicine and Prevention, the Journal of Service Research and the International Journal of Innovation Management, as well as the book Branding in Emerging Markets. He regularly publishes in Forbes, Pharma forum and other blogs. He appeared as a keynote speaker at various international life science events in healthcare.
Dr. Andreas Bilstein studied Biology at the University of Cologne and subsequently completed his doctorate at the Medical Faculty. After receiving his PhD, Dr. Bilstein acted in an executive position of the product development in a German-American biotech company that focuses on in vitro diagnostics. Since 2007 Dr. Bilstein has worked for bitop AG and has been significantly involved in the development of the medical device portfolio. After he was granted power of attorney in 2012, Dr. Bilstein was appointed a member of the executive board in 2014. On the executive board he is responsible for research and development.
Maria Agustina Duguine is a professional chemist, Italo-Argentine nationality, creator of a company dedicated to providing solutions for the industry. Formed in large multinationals (Bayer, Novartis), she has developed a system of GMP solutions with an exclusive and different treatment for each company-client, in order to facilitate the development of products and their export to the whole world. Today, the company has highly trained professionals in different areas, strategically located at three sites (Argentina, United States and Italy).
Dawn M. Ecker, M.S., Consultant and bioTRAK® Database Manager with BioProcess Technology Consultants, has over 25 years of experience in the biotechnology industry, ranging from from drug discovery, in vitro and in vivo screening, in vivo model development, pharmacokinetics, the manufacturing and purification of recombinant products and biopolymers and is highly skilled in secondary research required for biopharmaceutical market related analyses. At BioProcess Technology Consultants, she is responsible for managing the bioTRAK® database team and maintaining the company’s database for biopharmaceutical products, manufacturing capacity, and related topics, as well as for developing client-specific biopharmaceutical market-related analyses. Before joining BioProcess Technology Consultants, Ms. Ecker was a Research Fellow at the University of Massachusetts, Amherst where she managed the University’s Core Sequencing Facility, providing contract sequencing and real-time PCR services to the University community and several industrial clients. She also oversaw the day-to-day operations of the population genetics research laboratory and aided in the incorporation of high-throughput screening methods and equipment which enabled expedited research activities. Ms. Ecker holds a B.S. in Microbiology/Biotechnology from Quinnipiac University and an M.S. in Biology from Worcester Polytechnic Institute.
Pearl has worked over 15 years in the biotechnology industries to serve both operating and consulting roles for more than 30 biomedical projects. As Director of Project development, she operates in CMC, project management, project oversight, regulatory consulting and business development fields. Pearl’s educational credentials include a Bachelor of Nutrition and Health Science and a Master in Molecular Biology and Biotechnology. She has brought the very first biological medicinal product from preclinical to NDA approval in Taiwan.
Rolf Frey has a scientific education in chemistry and mathematics from the University of Heidelberg, Germany. Starting in 1982 as an account manager for Life Science products at Bio-Rad Germany he has worked in different positions in Sales, Sales Management and Marketing for Central Europe. Since the early 90’s his focus besides Capillary Electrophosis is directed to bioprocess chromatograph. Since 2010 he is heading a multinational team of dedicated highly skilled process chromatography specialists and application scientists for Bio-Rad’s business in Europe, Middle East and Africa.
I’m a lead of international division specialising in international trade and competition, with a strong background in economics and commerce. Throughout most of my career, I have been looking to expand into global markets. I have extensive experience in the formulation and execution of business development and expansion strategies, and I’ve seen great success in introducing products into emerging markets. In addition, I’m also familiar with global trade facilitation, supply chain and logistics management, and regulatory through my various roles.
Craig Johnston is Industry Director at (CMAC) Continuous Manufacturing and Advanced Crystallisation. Established in 2011, CMAC is a world-class international centre for manufacturing research and training. Its vision is to lead the world in crystallisation and the adoption of continuous manufacturing. Working in partnership with industry it is transforming medicines manufacture. Craig works with Tier 1 industry members (GSK, AZ, Novartis, Bayer, Pfizer, Takeda, Eli Lilly, Roche and Pfizer) and a range of technology companies. Craig is a Fellow of the Institute of Chemical Engineers and has a MBA. His previous industrial career spanned 22 years, working for ICI, Zeneca, Avecia and Fujifilm. Responsibilities included plant management, new product introduction, process improvement, capital expenditure and process technology leadership. He was a Board Director with Britest. He is co-founder of sustainable protein business 3f Bio Ltd.
Professor Kander is founding Dean of the Kanbar College of Design, Engineering and Commerce at Thomas Jefferson University (Philadelphia University + Thomas Jefferson University) where he teaches and does research in the areas of materials science, systems modeling, data visualization, and integrative design thinking. He is also Associate Provost for Applied Research at Jefferson. He received a BS in Chemical Engineering from Carnegie-Mellon University, and a PhD in Chemical Engineering from the University of Delaware. Before joining Philadelphia University (now Jefferson), he was founding Director of the School of Engineering at James Madison University (JMU), Department Head of Integrated Science & Technology at JMU, and a faculty member in the Materials Science & Engineering Department at Virginia Tech (VT). While at VT, he was also Director of the College of Engineering’s interdisciplinary “Green Engineering” program. Before joining academia, he was employed by DuPont in Wilmington, Delaware as a Senior Engineer in the Advanced Composites Division of the Fibers Department and in the Polymer Physics Group of the Central Research Department.
Director of Prestige BioPharam from Singapore. Michael has been working in the bio industry over two decades and professional antibody drug commercial developer and manufacturer.
Dr. Tae Han Kim has been Chief Executive Officer at Samsung BioLogics since the Samsung group diversified into the pharmaceutical business as the new growth engine for the next generation in April, 2011. Dr. Kim brings to biopharma industry innovative construction and operation know-hows through his extensive experience in various industries including electronics and petrochemical. Dr. Kim began his career with Samsung in 1979. Prior to joining Samsung BioLogics,
Dr. Kim served as Executive Vice President of Strategic Business Development at Samsung Group and held a senior leadership position for Samsung Total Petrochemicals, a joint venture company between Total of France and Samsung. While he led task force team to find Samsung group’s next growth engine, he saw the biopharma industry generally and the CMO space specifically in sustained growth pattern. Dr. Kim convinced Samsung Group to invest about $3 billion in the biopharma industry. Dr. Kim holds a doctoral degree in chemical engineering from the University of Texas at Austin.
IIn charge of Quantumzyme’s science and strategy, Naveen comes with over 20years of scientific &entrepreneurial experience in the drug discovery industry across the USA, Australia and India.Quantumzyme is a boutique enzyme engineering company focused on application of Quantum Mechanics, Molecular Modelling and Molecular Dynamics simulations to understand catalysis and provides the ability to rationalise suitable modifications to achieve the maximum benefit of biotransformationHe has published several research papers and the most notable was published in Nature July 2017with a few more interesting discoveries in the pipeline for the year.Naveen is an entrepreneur and hands-on executive officer with extensive knowledge of Pharma, Healthcare, regulatory and medical devices scenario in India. Solid Healthcare, Life Sciences background known for strategic and focused approach, with extensive accolades for establishing creative strategies for optimizing internal operations, financial returns, limiting risk, creating lean teams, and external customer service and output.Prior to founding Quantumzyme,he served as the CEO of Cryo Stemcell and prior to that as Director at Philips Research, where he was associated with a portfolio of opportunities for new business creation in healthcare and energy. In his previous roles, he has risen through the ranks -from being a bench worker at an Australian research institute to heading the strategic business unit of an American drug discovery informatics company. He has conceptualized and developed novel solutions for accelerating drug discovery and directed teams consisting of experts from different domains including chemistry, proteomics and systems biology. He has been instrumental in conceiving new ideas that are the basis for the company’s patent portfolio.
Eric Langer has over 25 years experience in biotechnology and life sciences international marketing, management, market assessment, and publishing. He has held senior management and marketing positions at biopharmaceutical supply companies. . He is an experienced biotechnology strategist, marketing practitioner, publisher, and researcher. He has published, edited and authored numerous books, reports, and major studies on topics including: Advances in Biopharmaceutical Technology in China, Advances in Large-scale Biopharmaceutical Manufacturing, Biopharmaceuticals in the US Market, cell culture reports, media, sera, tissue engineering, stem cells, diagnostic products, blood products, genetics, DNA/PCR purification, blood components, and many others. He lectures extensively on pricing and channel management topics, and teaches at Johns Hopkins University and American University: Biotechnology Marketing, Marketing Management, Services Marketing, Advertising Strategy, and Bioscience Communication. He has developed numerous courses, classes and seminar programs, including Marketing in a Regulated Environment, Marketing Technical Products, and TechniManagement.™ In 1989 he co-founded BioPlan Associates, Inc. a biotechnology and life sciences marketing company that provides information, market research, pricing, and market analysis to biotechnology and healthcare organizations. He has launched and managed marketing programs for product lines ranging from $500k to $500 million. His company works with both large and small clients at commercial biotechs, non-profit organizations, and governments in assessing and evaluating markets, and marketing strategies and tactics.
Sander Leeuwenburgh studied Materials Science & Engineering at Delft University of Technology and graduated at the Laboratory of Inorganic Chemistry in 2001 (cum laude). In November 2006 he obtained his PhD degree (cum laude). Thereafter, he continued his scientific career as a postdoc until March 2008, when he was awarded a Young Investigator Award (VENI) by the Dutch Technology Foundation STW and was appointed as assistant professor at the Department of Biomaterials. In the framework of his VENI fellowship, he was visiting scholar at the Department of Biomaterials at Kyoto University Medical Hospital (Kyoto, Japan) from August 2009 until January 2010. In June 2015 he was appointed as associate professor after obtaining a prestigious VIDI award that enabled him to start his research group on nanostructured biomaterials. Since June 2016 he is Principal Investigator at the Radboud University Medical Center. In April 2018 he was appointed as full professor Regenerative Biomaterials at Radboudumc. He published more than 125 peer-reviewed papers and has an h-index of 29 (Web of Science) or 37 (Google Scholar).
Mr. Dan Leorda, P.E. is a Sr. Director, EPCMV at IPS-Integrated Project Services, LLC located in Blue Bell, PA, USA and is responsible for providing Engineering, Procurement, Construction Management and Validation (EPCMV) solutions for clients. For over two decades he has provided leadership over fast-track design-build projects for the construction and operations of highly complex life sciences facilities. Mr. Leorda sets vision and guidance to the overall project delivery community within IPS. He develops strategies for EPCMV delivery, collaborating with partnering companies for successful outcomes. He also integrates innovation, modular delivery, and new technologies into the IPS overall project delivery process. Prior to IPS, Mr. Leorda spent several years in other industries working in engineering on large size infrastructure projects. Mr. Leorda holds a BS and MS in Civil Engineering from Drexel University and is a licensed Professional Engineer. He is an active member in the International Society for Pharmaceutical Engineering (ISPE) and American Society of Highway Engineers (ASHE). He has contributed as an IPS Tour Leader during the IPS Modular Construction Tour at INTERPHEX and has co-authored “The Modularization Process” published in Pharmaceutical Processing.
Senior Scientific Advisor, National Biologics Manufacturing Centre, a UK-based technology innovation centre part of the Centre for Process Innovation & the UK Catapult network. John has previously worked as a consultant to the biopharmaceutical industry. Prior to that he held senior bioprocess development roles at Fujifilm Diosynth Biotechnologies, Merck &Co, Avecia Biologics, Zeneca and ICI. John has almost 30years of broad experience in bioprocessing and protein chemistry. He has been directly involved in all phases of bioprocess development from early phase process definition to late phase process validation. He has been responsible for development and implementation of innovative bioprocess technologies.
Roxy Liu is Business Development Manager for Sinovac Biotech Co., Ltd. – a China-based biopharmaceutical Company that focuses on the R&D, manufacturing and commercialization of vaccines.
Her main mission in Sinovac is to establish long-time partnership with the distributors/vaccine manufacturers outside China. She hold a M. Sc. degree in Biochemistry.
Peter has over 13 years of experience in pharmaceutical and biopharmaceutical industries. Peter held various technical roles in process solutions for the biotech industry prior to moving into management positions in technical and sales roles. He has extensive knowledge of bioprocess manufacturing and helped design new facilities and retrofit existing facilities with single use technologies. Peter joined G-CON Manufacturing in 2016 where he now works with clients in designing pre-fabricated autonomous clean rooms.
Peter received his Bachelor of Science in Chemical Engineering and a Minor in Biomedical Engineering from Cornell University. He received is M. Eng in Chemical Engineering from Cornell University.
André Markmann received his Ph.D. in Biochemistry in 2001, and started thereafter his career in the pharmaceutical industry. He worked for global leading companies like Aventis and DSM, and is active for Biotechpharma as Vice President Business Development since September 2014.
Mr. Meek received his BS in Chemical Engineering from North Carolina State University, with a concentration in biochemistry.He has over 13 years’ experience in
business development for preclinical research proof of concept services including in vivo and in vitro efficacy models to stable cell line development. Mr. Meek has forged numerous collaborations with global cGMP service providers and CMC consultants facilitating the production of multiple new molecules that have resulted in positive clinical outcomes and significant financial milestones.He led Business Development and Marketing for Aragen
Bioscience.Under Mr. Meek’s leadership in business development, Aragen’s sales grew 15 fold resulting in the acquisition of the company by GVK BIO, one of the largest contract research organizations in Asia.
John Milne PhD is the Training Director at the National Institute for Bioprocessing Research and Training, Dublin, Ireland., with responsibility for the development
John Milne PhD is the Training Director at the National Institute for Bioprocessing Research and Training, Dublin, Ireland., with responsibility for the development
Killian O’Driscoll is the Director of Projects at the National Institute for Bioprocessing Research and Training (NIBRT). Killian is a Genetics Graduate from Trinity College Dublin with an MSc in the Management of Innovation from the University of London. He also is an Associate Lecturer in Project Management at Dublin Business School. Prior to joining NIBRT, Killian worked with Microsoft European Operations Centre as Senior Global Project Manager and with Ericsson Competence Development Centre in the area of technology education and development. Killian working closely with all stakeholders in the biopharmaceutical industry has been involved in the successful establishment of NIBRT which has numerous international accolades including ISPE Facility of The Year, Bioprocess International Manufacturing Collaboration of the Decade and NIBRT is now recognized as a global leader in biopharma research and training.
Jos Olijve graduated at University Groningen-Netherlands in 1983. From 1983 to 1986, he worked as a Researcher in the Department of Molecular Genetics at the same University, investigating the area of isolation and characterization of proteins involved in the Transformation of Bacillus subtilis with chromosomal DNA. In 1986, he joined FujiFim Manufacturing Europe B.V as Senior Engineer and Project Leader and was in charge of the application development of photographic gelatins and of the characterization and the development of medical recombinant gelatin products. He joined Rousselot, a Darling Ingredients Company in 2012 where he is responsible for the development of new gelatin products and new gelatin based applications. Jos Olijve has published 15 patent applications and author/co-author of 10 scientific papers.
James Park is the Senior Vice President and the Managing Director of the Global Business Development Centre responsible for BD Operation Team, BD Innovation Team and Integration & Marketing Part of Samsung Biologics. Prior to joining Samsung Biologics in 2015, Mr. Park held various technical and operational positions, as well as business development management leadership positions in biopharmaceutical companies in the U.S. Mr. Park began his career in 1989 with ALZA Corporation, a subsidiary of J & J, as a chemical engineer where he participated and led process and product development, technology transfer, validation and commercialization of several OROS products. He then worked in Technical & Alliance Management at Watson Pharmaceuticals. Transitioning to Merck as a Change Agent/Six Sigma Project Manager, Mr. Park then managed the Operational Excellence projects related to process improvements, cost savings and quality initiatives. From 2004 to 2015, Mr. Park participated in and directed 100+ CMC due diligences on assets ranging from pre-clinical to commercial products, and managed Global Manufacturing & Supply BD activities including Licensing, Outsourcing and M&A at Bristol-Myers Squibb. Mr. Park has over 25 years of experience in the biopharmaceutical and pharmaceutical industries
Amy Peck is the founder & CEO of EndeavorVR, a leading global VR/AR strategy & consulting firm. Amy speaks regularly on Enterprise VR/AR and has long been an evangelist for this technology. She holds several advisory board roles, is Co-chair of the VRARA Enterprise Committee and is an active mentor and member of several organizations including Women in Tech, Women in AR/VR and Sheryl Sandberg's Lean In Circles.
Amy's passion for virtual reality began at Leap Motion where she launched the Enterprise division working with clients across every major vertical including healthcare, entertainment, retail, hospitality, education and government. She helped these clients adopt VR & AR for both internal and customer-facing initiatives, often pairing them with talented developers and platform partners to bring these solutions to fruition.
It became clear that there was a need to help foster VR/AR development in the commercial arena and more importantly, shepherd these critical early wins. EndeavorVR was conceived for this very purpose.
Her own personal mission is to see VR/AR fundamentally improve every aspect of our lives
After obtaining Ph. D in Chinese Academy of Sciences in 2000, Dr. Sam Peng did post-doctorate research in the University of Warwick, UK for more than one year. Then he joined New York University Medical School as Research Scientist from 2003 to 2008. He is now the biopharmaceutical R&D manager of Limin International group Limited.
Saphia Rachidi graduated from the University Katholieke Universiteit Leuven as a chemical Engineer. She started working for Dow Corning in 2010 giving technical support to customer for different industries like performance chemicals, coatings, etc. In 2011 she moved to the role of manufacturing engineer where she was responsible for the production processes of antifoam compounds and granulated antifoams. In 2014 she moved to R&D developing and improving production processes for emulsions, granulated antifoams and compounds. In 2017 she joined the
medical healthcare team in Dow Silicones Corporation focussing on technical support of customers and developing tubing for biopharma processing.
Richard Richieri is the Head of Biologics Manufacturing at Syngene, and is responsible for the GMP operations and batch execution. Mr. Richieri has over 25 years’ GMP experience in biotechnology and has several publications regarding large scale processing to his name. He is technically knowledgeable in all aspects of cell culture and microbial based GMP production. He has experience of being responsible for the production of >100 clinical and commercial batches and has represented GMP operations during regulatory inspections, including PAI.
Philip joined Cobra in 2004 and is currently Sales and Marketing Director responsible for commercial sales activities within Europe and Asia and also overseeing the global marketing for Cobra with its three sites based in the UK and Sweden. Before Cobra, Philip had over 10 years of experience in various sales and marketing positions for diagnostics, large pharma and FMCG companies working both in Europe and Asia. Philip holds a BSc in Biology and French with a CIM qualification, having studied both in the UK and France
Product strategist, experience designer, and digital transformation expert, Nicola is currently part of the Accenture Digital UKI where he is the Go-To Market Lead for XR (AR,VR, and MR). A key part of his role is to use User Centric Design and Digital Transformation frameworks to create innovative and transformational solutions using immersive technologies. Nicola he’s also part of the BIMA (British Interactive Media Association) immersive technologies think tank where he helps defining best practices and advantages of using immersive technologies. With more than 15 years of experience in the media and entertainment industry, Nicola worked for companies like Atari, Google, Spotify, Yahoo!, Virgin Radio and IBM iX designing B2E, B2B and B2C digital products and numerous App Store hits
Dr. Ruotsalainen is a Senior R&D scientist at Admescope developing different analytical platforms for biopharmaceuticals. He has a broad background in bioanalytical development in clinical diagnostics industry.
Giorgio is part of the Business Unit, with responsibility of coordinating Business Development and Post sales activities
He joined BSP Pharmaceuticals in 2008 as Manufacturing Manager; in this role he was an active member of the team in charge of building up the manufacturing plant, including mechanical installation of all the equipments, completion of commissioning and qualification of the lines, start up of production.
In 2014 he moved to Business Development to support the strategic growth of the Company.
Prior to joining BSP Pharmaceuticals, Giorgio has achieved a significant experience in Manufacturing and Operation at Bristol Mayers-Suibb where developed his professional and technical growth.
Giorgio holds a degree in Pharmaceutical Chemistry and Technologies from the University of Perugia
Dr. Ujwala V. Salvi has over 15 years of experience across the Global and local Pharmaceutical/CRO, Tier I Medical Devices and BPO industry. She is Doctorate in Applied Biology & MBA in Healthcare from Indian Institute of Management, Kolkata. Trained in Six Sigma Black Belt and various Project management tools, with core experience in a wide range of Therapeutic Areas and worked at all stages of clinical development from Phase II to production of clinical documentation necessary for product license applications. She has worked in large global operations, managed strategic relationships, and played a key role in winning new business, setting up off-shored partnerships and in identifying new BU service lines and growing existing ones. Her areas of expertise include Clinical Trial operations, Risk Based Monitoring, Medical Writing and data publication, PVG, and feasibilities of new drug development and Analytics. She is an industry expert, has been involved in key global industry forums such as the DIA, SCDM, CII and CPHI.
Andrew Sandford is Vice President of Business Development at Catalent Biologics with responsibility for leading an international team of highly skilled business developers chartered to meet and exceed revenue objectives. Andrew has 24 years of experience in business development and marketing. He joined Catalent Biologics from Selexis where he was VP of Business Development. Previously, he held positions at Lonza/Cambrex, DOW Chemical, and GE. Andrew holds a B.Sc. in Microbiology from State University of New York at Plattsburgh.
Dr. Marinella Sandros currently is the business development manager for life Sciences and SPRi product manager at HORIBA Scientific. She also currently holds an adjunct assistant professor position in the department of Nanoscience at the University of North Carolina at Greensboro since August 2015. Previously, she held a full time assistant professor position in the nanoscience department from 2010-2015. Her doctoral training was in bioinorganic chemistry from Wayne State University followed by her postdoctoral fellowship in biomedical engineering at McGill University. Dr. Sandros has extensive expertise in synthesizing and characterizing various types of nanomaterials to enhance their biointerfacing properties using different methods of coatings for biological applications. Furthermore, she has over 12 yrs experience in developing novel fluorescent, Raman and Surface Plasmon Resonance imaging (SPRi)-based biosensors through the integration of nanomaterials with biological interfaces. Finally, Dr. Sandros has authored numerous high impact journals demonstrating her strong expertise in developing, characterizing and applying nanomaterials.
Peter Shapiro, PhD, is the Editor-in-Chief of PharmSource and he is also leading the integration of BioPharm Insight, Lead Sheet and PharmSource into GlobalData. Peter previously served as the Director for the Drug, Companies, News and Deals databases for GlobalData’s Pharma Intelligence Center. Prior to joining GlobalData, Peter was an Assistant Manager at Target Health, a Contract Research Organization (CRO) where he helped a diverse set of clients with the demands of bringing biologics, devices, and drugs to the market successfully. Peter also worked in small molecule drug development for Abbott Labs and on in vitro diagnostics at Ambergen, a diagnostic startup. Peter holds a PhD in Molecular and Cellular Biology from the Sackler Institute of New York University and is located in GlobalData’s office in New York City.
Kevin Sharp is a Business Development Lead within the Global Business Development Center of Samsung Biologics. Mr. Sharp leads the establishment of development, clinical and commercial manufacturing partnerships.
Prior to joining Samsung Biologics, Mr. Sharp held various commercial and business development positions in pharmaceutical companies in the U.S.
Mr. Sharp began his career in the pharmaceutical industry with GlaxoSmithKline, serving in various procurement roles supporting their biologics, pharmaceutical and consumer healthcare businesses. He then worked in a Business Development role managing the sale of GSK’s capacity as a Contract Manufacturer. Transitioning to Contract Pharmacal Corp. as a Business Development Director, Mr. Sharp then managed global pharmaceutical CDMO activities.
Robert is the CTO and co-founder of EnzBond Ltd which spun-out of Oxford University in 2016. Following this, EnzBond has revolutionised the biocatalysis sector with its propriety technology and is focused on making a dramatic change to how the chemical sector manufactures its products.
Dan Stanton is editor and founder of BioProcess Insider, an online publication focused on reporting the latest business news and opinion across the biomanufacturing space, and part of the BioProcess International brand. Formerly editor of Biopharma-Reporter and in-Pharmatechnologist, Dan has particular expertise in biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development. Dan is a native Londoner now based in Montpellier, France.
Paul Thorning is a co-founder and Chief Executive Officer of CrystecPharma. He has over 25 years’ experience in the chemical and pharmaceutical industries in manufacturing, research, marketing, consultancy and senior executive roles. Paul was a former licensing director for AstraZeneca (member of Crestor acquisition team). Away from the pharmaceutical industry, Paul spent three years in Tanzania, Africa, where he was a programme director responsible for a team running hospitals, health programmes and community services for 140,000 Congolese refugees. Paul was subsequently appointed as Director of the Institute of Pharmaceutical Innovation at the University of Bradford, where he was actively involved in innovation in pharmaceutical sciences including the establishment of 3 innovation-based companies. Paul is a Non-Executive Director of Medilink North, and was appointed as the UK’s Focal Point for Health and Innovation with China. Paul speaks English, French, Italian and Swahili and intermediate Mandarin, holds an MBA and professional membership of the Institute of Marketing, and is a Fellow of the Institution of Mechanical Engineers
Les Tillack is a Brisbane-based Biotech Expert and Entrepreneur whose perseverance, innovation, and ambition have all earned him the reputation as a seasoned industry leader. Les Tillack obtained a Bachelor of Science (B.Sc.) degree in Microbiology and a Bachelor of Engineering (B.E.) degree in Chemical Engineering from The University of Queensland. Les began working in the clinical pathology field in Brisbane. After 11 years, he was named Director of Operations at Progen Pharmaceuticals for another decade, where he spearheaded Progen’s anti-cancer drug PI-88’s progression from the preclinical stage to phase three manufacturing. Currently, Les Tillack serves as the CEO and Managing Director of Luina Bio (formerly known as PharmaSynth and previously affiliated with Progen), which is Australia’s frontrunner in the biopharmaceutical contract manufacturing space. At Luina Bio he has assembled a talented team that routinely delivers scientific excellence for their customers. In 2017, the company won the Queensland Export Award for Health & Biotechnology. Les strives to provide strategic advocacy to the biotechnology industry through new drug development for the greater good of humanity as a whole.
Marit van der Heijden holds a Master’s degree from the RSM Erasmus University in Rotterdam. She started her career in 2008 at SABIC, being (co)responsible for the introduction of certified bio based polymers, coordinating Life Cycle assessments, and working in the pricing team. In 2014, she joined Anova Seafood as CSR and Marketing Manager, being responsible for marketing unique propositions to European retail customers. In April 2018, she joined Rousselot as Marketing Manager. In this role, she is responsible for the global marketing activities for the Rousselot gelatin products.
Dr. Hosia is a Senior R&D scientist at Admescope developing LC-MS based analysis for biopharmaceuticals. He has a long history in bioanalytic and LC-MS in both, academia and private sector.
Alexander Werner is Chief Business Officer at The Biosimilars Group since May 2018. He is responsible for business development and for the supervision of integrated biosimilar projects.
Alexander has 18 years of experience in drug development holding various managerial positions in developing biotechs and as business developer of service providers with a strong focus on the preclinical phase of biologics. Prior to his current position he was consultant for regulatory affairs at Granzer, co-founder of the biotech spin-off Imevax and contributed as responsible project manager to the transition of an academic vaccine project into clinical testing. Alexander graduated in biology and holds a PhD (summa cum laude) in neurobiology from the Max-Planck-Institute.
Ryan leads Quay Pharma clinical development service business for Live Biotherapeutic drug products. He has championed multiple projects working on both single strain and consortia products for both Phase I and Phase II clinical studies; involving both IMPD and IND submissions. Ryan has over 20 years’ experience spanning various technical, CMC outsourcing and programme management roles in the pharma and biotech sectors. He worked for Oxyrane as Head of Project Development and SSL innovation as their Innovation Manager.
Dr. Sofiya Yashchuk is a Technical Applications Specialist supporting Roquette’s BioPharmaceutical ingredients, used in manufacturing processes and formulation of biologic drugs. Roquette has a well-established history in manufacturing plant derived carbohydrates, polyols, and cyclodextrins; Sofiya supports technical development of these existing tools in biopharma applications, and drives the development of novel solutions to meet the challenges of biologic drugs production. Previous to joining Roquette, Sofiya worked at BASF Corporation as Business Development Manager in the Pharma Ingredients & Services division, where she also focused on ingredients for the BioPharmaceutical segment. Sofiya holds a Bachelor's Degree in Biochemistry from the University of Illinois and a PhD in Organic Medicinal Chemistry from Purdue University
Samet Yildirim received a BSc in Biology and an MSc in Biophysics from Ankara University and an MBS degree in bioprocessing and business of bioscience from Keck Graduate Institute of California. From 2008 to 2013 he held various positions within responsibilities for research, product innovation and business development in various life science companies. In 2013 he joined Boehringer Ingelheim in Fremont, CA and involved with the development of continuous process platform. Currently he is leading a global innovation portfolio for the Next Generation Manufacturing of biopharmaceuticals in Boehringer Ingelheim Biopharma Business Unit